

Index to Volume Twenty-three

Index of Issues: January–February, 1–92; March–April, 93–170; May–June, 171–260; July–August, 261–350; September–October, 351–444; November–December, 445–534.

INDEX OF AUTHORS

A

Abellanos I, 407
Acosta-Cázares B, 283
Anderson ES, 357
Anderson RM, 248, 312
Anderson RM, 312
Andersson-Ellström A, 234
Andrews E, 429
Aral SO, 1, 9, 248, 395
Arany I, 475
Arvelo M, 40
Ascunce N, 504

B

Baro'n AE, 190
Barnes FG, 342
Barrow JC, 481
Baumrind N, 157
Beck-Sague CM, 342
Becker TM, 138
Beebe JL, 465
Bein M, 370
Bell G, 498
Benes S, 127
Beyrer C, 198, 264
Black CM, 342
Blackburn D, 304
Blount JH, 68
Blythe MJ, 226
Bodin L, 384
Boily M-C, 312
Bolan G, 157
Bonnez W, 273
Borg AJ, 494
Bosch FX, 504
Bromberg J, 333
Brown K, 342
Burczak J, 97
Burk RD, 333

C

Cabral RJ, 511
Calderón-Jaimes E, 120
Canavaggio M, 402
Cargill V, 357
Carlson RG, 277
Cartwright ID, 181
Castro C, 366
Castro LAA, 206
Catania JA, 522
Cates Jr. W, 68
Celentano D, 198, 264, 446
Cevenini R, 177
Chen S, 494
Cheung MM, 103
Chmiel JS, 453
Choi A, 273
Choueiri B, 97
Claassen E, 206

Clark AM, 461
Cohn DL, 304
Conde-Glez CJ, 120
Cordts JR, 342
Corey L, 273
Crumble D, 357
Cummings MC, 127, 366

D

D'Antuono A, 177
d'Arcy SJ, 273
Daling JR, 138
Danielsson D, 384
Day S, 498
De La Court A, 413
de Sanjosé S, 504
DeHovitz JA, 333
Del Río-Chiriboga C, 120
Delea TE, 429
Demeo LR, 366
Demeter LM, 273
Dickerson MC, 429
Dickes JR, 299
DiFrancisco W, 446
Dillner J, 234
DiSantostefano R, 206
Donati M, 177
Douglas Jr. JM, 190
Doyle L, 51

E

Ehret JM, 270
Eiumtrakul S, 198, 264
Ellen JM, 511
Ellish NJ, 446
Eluf-Neto J, 504
Escobedo de la Peña J, 283
Eskenazi B, 239
Evans M, 304

F

Fairley CK, 494
Falck RS, 277
Fantry L, 370
Farley TA, 1
Farr G, 206
Faxelid E, 289
Feldman J, 333
Fenstermacher H, 219
Fichtner R, 511
Fife KH, 174
Finney S, 219
Flock ML, 16
Forslin L, 384
Forssman L, 234
Forster GE, 378
Francis DP, 351
Friedman SR, 523
Friis S, 471

Frisch M, 471
Fuqua RW, 357

G

Garland SM, 494
Garnett GP, 248, 498
Gaydos CA, 402
Georges S, 151
Gershman KA, 481
Ghani AC, 498
Gibson JJ, 40
Gili M, 504
Goh BT, 378
Goldbaum GM, 109
Golden MR, 370
Gonzalez LC, 504
Greenspan JR, 16
Guerrant RL, 517
Gun-Munro J, 115
Gust CH, 494

H

Hagmar B, 234
Hammond GW, 93
Handsfield HH, 171
Handsfield HH, 248
Heckman TG, 357
Heltzel DM, 465
Hernández-Avila M, 120
Hessol NA, 157
Hillier SL, 461
Hillier SL, 489
Ho NKY, 103
Hoffman RG, 357
Holmes KK, 258
Hook III EW, 5
Hoover DR, 370
Horton T, 219
Hughes JP, 248
Illuminati L, 181

I

Ison CA, 378
Ison CA, 498
Izarzugua I, 504

J

Jackson HD, 494
Jean Paul C, 151
Johanson J, 402
Johnston J, 429
Jones RB, 226
Jorgensen BB, 471
Jossens MOR, 239
Juárez-Figueroa L, 120
Judson FN, 190
Judson FN, 270
Jules BA, 151
Jungkind D, 465

K

Kam KM, 103
Kamwendo F, 384
Kato I, 504
Katz BP, 226
Keawvichit R, 264
Kelly JA, 357, 333
Khamboonruang C, 264
Kidder GG, 461
Kilmarx P, 16
Kingham GR, 498
Kitchen V, 413
Knapp JS, 342
Kraaz W, 293
Krantz I, 289
Kuntolbutra S, 198

L

La Placa M, 177
Landesman SH, 333
Langer LM, 511
Larsen SA, 342
Latman NS, 219
Ledru S, 151
Lee F, 138
Lee H, 97, 402
Lees MI, 494
Leverette W, 40
Lewis DA, 378
Lo KK, 103
Longstreth Jr. WT, 184
Luger A, 392
Luinstra K, 115
Lukhart SA, 184, 366
Lyn P, 115

M

Maclean S, 392
Mahony J, 115
Marine WM, 190
Marra C, 366, 184
Martin DH, 445
Masters H, 465
Maxwell CL, 184
McCormack WM, 127, 366
McGill WL, 190
Melbye M, 471
Mercer MB, 357
Migliorini G, 494
Miller JR, 517
Millsom I, 234
Mohamed F, 151
Moreo P, 504
Morse SA, 342
Moses S, 262
Muñoz N, 504

N

Nahmias AJ, 138

Nakashima AK, 16
 Narramore J, 24
 Natpratan C, 264
 Ndulo J, 289
 Negosanti M, 177
 Nelson KE, 198, 264
 Neumann MS, 131
 Ngeow YF, 402
 Nichter M, 353
 Nichter M, 407
 Nicolas M, 151
 Nims LJ, 270
 Noell J, 30
 Norman AD, 357

O

O'Keefe K, 304
 Oakes D, 273
 Olguin F, 206
 Osewe PL, 230
 Ostrow DG, 453
 Oxman GL, 30, 51

P

Padian NS, 157
 Pappas PG, 273
 Patterson TL, 145
 Patton DL, 461, 489
 Perkins T, 370
 Perry MJ, 357
 Peterman TA, 230
 Petty M, 181
 Phillips EA, 425
 Priddy FH, 157

Q

Quinn TC, 402

R

Rabe LK, 461, 489
 Raevsky C, 304
 Rank RG, 145
 Ransom RL, 230
 Reichman RC, 273
 Rein MF, 517
 Reingold AL, 157
 Reyes M, 181
 Richardson H, 115
 Ridderhoff JC, 342
 Robinson D-T,
 Roffman RA, 357
 Rolfs RT, 16
 Rompalto AM, 370
 Rothenberg RB, 24, 68
 Ruiz-Maya L, 283
 Rumpianesi F, 177
 Rylander E, 293

S

Sapp M, 234
 Schachter J, 239, 261
 Schiller J, 234
 Schluter W, 190
 Schmid GP, 45
 Schwebke JE, 299
 Shaffer J, 366
 Shah KV, 504
 Shih M, 517
 Shlay JC, 304
 Shultz TR, 425

Siegal HA, 277
 Sikkema KJ, 357
 Smaill F, 115
 Smith BL, 127, 366
 Smolkowski K, 30
 Solomon LJ, 357
 St. Louis ME, 1, 58
 Stary A, 97
 Steyrer K, 97
 Stoler MH, 273
 Stoner BP, 248
 Strand A, 293
 Suprasert S, 198
 Sweeney YC, 461, 489
 Sweet RL, 239

T

Tabrizi SN, 494
 Tafur L, 504
 Tanfer K, 395
 Tapsall JW, 425
 Tembo G, 289
 Thacker C, 425
 Theetranont C, 198
 Tomazic-Allen S, 97
 Tormo M-J, 504
 Tying SK, 475

U

Uribe-Salas F, 120
 Uribe-Zúñiga P, 120

V

Van der Pol B, 226

Vermund SH, 333
 Viladiu P, 504
 Vittinghoff E, 157

W

Wagstaff DA, 357
 Walboomers JMM, 504
 Wang J, 277
 Ward H, 413, 498
 Weber J, 498
 Weinberg A, 465
 Weisman CS, 446
 Welsh LE, 402
 White A, 429
 Whittington WL, 24
 Wilander E, 293
 Winett RA, 357
 Wing PW, 103
 Wongworapat K, 264
 Wood RW, 109
 Wright NH, 198
 Wroten JE, 230

Y

Yu T, 109

Z

Zaidi AA, 230
 Zehbe I, 293
 Zenilman JM, 198, 213, 370, 446
 Zhang Z-F, 415
 Zimmerman RS, 511
 Zuckerman RA, 299

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970; Section 3685. Title 39 United States Code) Date of Filing—October 1, 1996. Title of Publication—SEXUALLY TRANSMITTED DISEASES; Frequency of Issue—Bimonthly; Annual Subscription price—\$150.00; Location of Known Office of Publication—12107 Insurance Way, Hagerstown, MD 21740; Location of the Headquarters of General Business Offices or the Publisher—Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Publisher—Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Editor—Julius Schachter, M.D., 1001 Potrero Ave., Bldg. 30, Room 416, S.F. General Hospital, San Francisco, CA 94110; Managing Editor—Jeanne Moncada, 1001 Potrero Ave., Bldg. 30, Room 416, S.F. General Hospital, San Francisco, CA 94110; Owner—American Sexually Transmitted Diseases Association, c/o Denver Public Health, 605 Bannock St., Denver, CO 80204; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent of more of total amount of bonds, mortgages, or other securities—None. A. Total no. copies printed (*net press run*), average 2,067, actual 2,100; B. Paid circulation none. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 1,447 actual 1,480; C. Total paid circulation, average 1,447, actual 1,480; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 72, actual 120; E. Free distribution outside the mail, average, none, actual none. F. Total Free distribution (*sum of D and E*), average 72, actual 120. G. Total distribution (*sum of C and F*), average 1,519, actual 1,600; H. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 548, actual 500. 2. Returns from news agents, none; I. Total (*Sum of G, H1 and H2*), average 2,067, actual 2,100. I certify that the statements made by me above are correct and complete. Beverly V. Dietrich, *Circulation Director*.

INDEX OF SUBJECTS

A

- Acquired immunodeficiency syndrome (AIDS), nurses' knowledge, experiences and attitudes about, 219
- Acyclovir, nonprescription use of, 171, 174 (editorials)
- Adolescents
 - crack use and STD incidence in, vs. in adults, 511
 - female, declining chlamydia incidence in, 226
- Africa
 - Burkina Faso, female genitourinary infections rates in, 151
 - Ghana, HIV-2 seroprevalence in, 526 (editorial)
 - STD and HIV treatment in, 262 (editorial)
- Age, cervicovaginal HPV prevalence and, 333
- Anal intercourse, HIV transmission and, 481
- Anogenital warts, scissors excision of, 273
- Antibiotics, self-medication with, for STD prevention, 353 (editorial), 407
- Antibiotic susceptibility, of *N. gonorrhoeae*, 213, 379
- Australia, quinolone-resistant *N. gonorrhoeae* in, 425
- Azithromycin, decreased susceptibility to, by *N. gonorrhoeae* isolate, 270

B

- Bacterial vaginosis
 - incidence and prevalence of, in females in Burkina Faso, Africa, 151
 - polymorphonuclear neutrophil absence in, 489
- Burkina Faso, female genitourinary infections rates in, 151

C

- Cancer, penile, syphilis and, 453
- Candidiasis, incidence and prevalence of, in females in Burkina Faso, Africa, 151
- Case-finding
 - for syphilis, screening vs. contact tracing in, 51, 441 (letter)
 - in Zambia, 289
- Centers for Disease Control
 - pelvic inflammatory disease treatment guidelines, compliance with by primary care physicians, 157
 - telephone hotline, caller profile for, 131
- Cerebrospinal fluid, *T. pallidum* detection in, without VDRL test, 392
- Cervicovaginal human papillomavirus, age-related incidence decline in, 333
- Chancroid, laboratory diagnosis of, CDC survey of, 342
- China, *Trichomonas vaginalis* risk factors in, 415
- Chlamydia trachomatis*
 - antibodies to, HPV DNA detection and, 504
 - detection of, ligase chain reaction for, 177
 - female infection rates for, in Burkina Faso, Africa, 151
 - laboratory diagnosis of, CDC survey of, 342
 - ligase chain reaction detection of, 177
 - h2vs. polymerase chain reaction, 97
 - with urine specimen, 402
 - male infection with, immune response in, guinea pig model for, 145
 - PID in, declining incidence of, 384
 - prevalence and predictors of, vs. in gonorrhea, 465
 - prevalence and risk factors for, in Mexico, 283
 - Syva MicroTrak enzyme immunoassay for, confirmation of with Syva Direct Specimen test, 494
 - tampon-collected specimens for, 461, 127
 - in teenage girls, declining incidence of, 226
 - VIDAS enzyme-linked fluorescent assay for, 115
- Ciprofloxacin
 - dosage of, for gonorrhea, 165 (letter)
 - N. gonorrhoeae* susceptibility and, 213
- Clinical Laboratory Improvement Act, 342
- Cocaine use. *See also* Crack cocaine; Drug abusers
 - anal intercourse and, HIV transmission and, 481

Commercial sex workers

- antibiotic self-medication in, for STD prevention, 353 (editorial), 407
- spermicide and condom use by, 206
- syphilis in, incidence, prevalence, and determinants of, 120
- Condoms
 - nonoxynol-9 in, genital tract inflammation and, 446, 413
 - use of
 - by drug abusers, 277
 - by inner-city women, predictors of, 357
 - self-reported
 - reliability of, 471
 - validity of, 76, 77 (letters)
 - spermicides and, in sex workers, 206
- Condyloma acuminatum, scissors excision of, 273
- Contact tracing
 - vs. screening, in syphilis case-finding, 51, 441 (letter)
 - in Zambia, 289
- Core group, meaning and suitability of, in STD terminology, 164 (letter)
- Crack cocaine. *See also* Drug abusers
 - STD incidence and, in adolescents vs. adults, 511
 - STDs incidence and, drug-sex behavior and condom use and, 277
- CSF-FTA-ABS, in diagnosis of neurosyphilis, 392

D

- Dark-field microscopy, for *T. pallidum* detection in early syphilis, vs. ELISA, 366
- Developing countries. *See also* Africa
 - STD and HIV treatment in, 262 (editorial)
- DNA amplification, for *C. trachomatis* detection, in first-void urine, 97
- Drug abusers. *See also* High-risk behavior
 - STDs in
 - in adolescents vs. adults, 511
 - drug-sex behavior and condom use and, 277
- Drug resistance. *See also* specific drugs and organisms
 - of *N. gonorrhoeae*, 213
- Ducrey, Augusto, 93

E

- ELISA, for *T. pallidum* detection in early syphilis, 366
- Endocarditis, gonococcal, case report of, 181
- Enzyme immunoassay, Syva MicroTrak, for *C. trachomatis*, confirmation of with Syva Direct Specimen test, 494
- Epidemiology, of syphilis, 1 (editorial), 9, 16
- Erythromycin, resistance to, by *N. gonorrhoeae* isolate, 270

G

- Genital ulcer disease, HIV transmission and, 429
- Genitourinary infections, female, etiology of, in Burkina Faso, Africa, 151
- Ghana, HIV-2 seroprevalence in, 526 (editorial)
- Gonococcal endocarditis, case report of, 181
- Gonorrhea. *See also* Neisseria gonorrhoeae
 - association of with HIV, measures and study design for, 312
 - ciprofloxacin dosage for, 165 (letter)
 - female infection rates for, in Burkina Faso, Africa, 151
 - in HIV, impact of early intervention on, 370
 - laboratory diagnosis of, CDC survey of, 342
 - PID in, declining incidence of, 384
 - prevalence and predictors of, vs. in chlamydia, 465
 - transmission of, partner networks and, 498
- Guinea pig inclusion conjunctivitis, male immunity to urethral *C. trachomatis* infection and, 145

H

- Haemophilus ducrey*, detection of, history of, 93
- Hepatitis B, seroprevalence of, in Southwestern Hispanic women, 138
- Hepatitis C, seroprevalence for, in Southwestern Hispanic women, 138
- Herpes simplex virus, seroprevalence of, in Southwestern Hispanic women, 138
- High-risk behavior. *See also* Safe sex practices
- HIV transmission and, 481
 - in homosexual men, 109
 - partner reports of, reliability of, 471, 517 (editorial)
 - self-reported, reliability of, 471
- Hispanics, Southwestern, HSV, hepatitis B and hepatitis C seroprevalence in, 138
- Homeless population, HIV seroprevalence and risk factors in, 304
- Homosexual men
- unsafe sex practices among, 109
 - unsafe sex practices in
 - HIV transmission and, 481
 - self-reported, reliability of, 471
 - unsafe sexual practices in, partner reports of, reliability of, 471, 517 (editorial)
- Hong Kong, *N. gonorrhoeae* quinolone resistance in, 103
- Hotline, CDC, caller profiles for, 131
- HPV DNA detection, risk factors for, in middle-aged women, 504
- Human immunodeficiency virus infection
- association of with other STDs, measures and study design for, 312
 - in developing countries, treatment of, 262 (editorial)
 - early intervention for, gonorrhea incidence and, 370
 - incidence of
 - in females in Burkina Faso, Africa, 151
 - in homeless population, 304
 - lifelong early intervention program for, 351 (editorial)
 - network methodologies and contact tracing for, 498, 522 (editorial)
- neurosyphilis in
- diagnosis of without VDRL test, 392
 - post-treatment resolution of serum and CSF abnormalities in, 184
- post-test counseling for, by telephone, 190
- prevention of, safe sex practices and. *See* Safe sex practices
- risk factors for
- in homeless population, 304
 - sexual adventurism and high-risk behavior as, 481
 - sexual intercourse during menstruation and, 395
 - STD incidence and prevalence in, 230
 - STD self-treatment and, in Thai men, 264
 - testing for, in inner-city women, predictors of, 357
 - transmission of, genital ulcer disease and, 429
 - type 2, seroprevalence of, in Ghana, 526 (editorial)
- Human papillomavirus infection
- cellular immunity in, interferon response and, 475
 - cervicovaginal, age-related incidence decline in, 333
 - detection of, in middle-aged women, risk factors for, 504
 - penile epithelial lesions in, histopathologic examination of, 293
 - risk factors for, 234
 - age at coitus debut and sexual activity as, 234

I

- Immunization, *C. trachomatis*, in male guinea pig model, 145
- Inner-city women, condom use and HIV test-seeking in, predictors of, 357
- Interferon, HPV response to, cellular immunity and, 475
- Intravenous drug users. *See* Drug abusers

L

- Lactoferrin assay, in genital tract infection screening, 489
- Ligase chain reaction, for *C. trachomatis* detection, 177
- vs. polymerase chain reaction, 97
 - with urine specimen, 402

M

- Menstruation, sexual intercourse during, self-reported STD history and, 395
- Mexico, chlamydia in, prevalence and risk factors for, 283
- Monoclonal antibody staining, for *T. pallidum* detection in early syphilis, vs. ELISA, 366

N

- Neisseria gonorrhoeae*. *See also* Gonorrhea
- antibiotic susceptibility of, quinolones and, 213
 - female infection rates for, in Burkina Faso, Africa, 151
 - isolate of, with erythromycin resistance and decreased azithromycin susceptibility, 270
 - quinolone-resistant
 - in Australia, 425
 - in Hong Kong, 103
 - tetracycline-resistant, 379
- Networks methodologies
- in HIV contact tracing, 522 (editorial)
 - in STD contact tracing, 498
- Neurosyphilis
- diagnosis of, without VDRL test, 392
 - serum and CSF abnormalities in, post-treatment resolution of, in HIV infection, 184
- Nongonococcal urethritis, history of, 86 (Parran lecture)
- Noxynol-9
- in chlamydial infection prophylaxis, 446
 - genital tract irritation and, 446, 413
- Nurses, knowledge, experiences and attitudes of, about AIDS, 219

P

- Partner networks
- in HIV transmission, 522 (editorial)
 - in STD transmission, 498
- Partner notification
- vs. screening, in syphilis case-finding, 51, 441 (letter)
 - in Zambia, 289
- Partner reports, of sexual behavior, reliability of, 471, 517 (editorial)
- Pelvic inflammatory disease
- gonorrhea and chlamydia associated, declining incidence of, 384
 - management of, by primary care physicians, 157
 - risk factors for, 239
- Penile cancer, syphilis and, 453
- Penile epithelial lesions, in human papillomavirus infection, histopathologic examination of, 293
- Polymerase chain reaction, for *C. trachomatis*
- in ligase chain reaction, 97
 - tampon-collected specimens for, 461
- Polymorphonuclear neutrophils, absence of, in bacterial vaginosis, 489
- Post-test counseling, for HIV, by telephone, 190
- Prostitutes. *See* Commercial sex workers

Q

- Quinolone, *N. gonorrhoeae* susceptibility to, 213
- in Hong Kong, 103

R

- Race, syphilis and, 1 (editorial), 9

S

- Safe sex practices
- decline in, among male homosexuals, 109
 - partner reports of, reliability of, 471, 517 (editorial)
 - self-reported, reliability of, 471
- Scissor excision, of condyloma acuminatum, 273
- Screening
- for genital tract infections, lactoferrin assay for, 489
 - for syphilis
 - vs. contact tracing, 51, 441 (letter)
 - serologic, 45

tuberculosis, in STD clinic population, 299

Self-reporting, of sexual behavior, reliability of, 471

Serologic screening, for syphilis, 45

vs. contact tracing, 51, 441 (letter)

Serum FTA-ABS, in diagnosis of neurosyphilis, 392

Serum TPHA, in diagnosis of neurosyphilis, 392

Sexual behavior. *See also* Safe sex practices

as HIV risk factor, 481

partner reports of, reliability of, 471, 517 (editorial)

self-reported, reliability of, 471

Sexual intercourse, during menstruation, self-reported STD history and, 395

Sexually transmitted disease clinic attendees

sexual mixing patterns among, 248

tuberculosis screening in, 299

Sexually transmitted disease hotline, caller profile for, 131

Sexually transmitted diseases. *See also* specific diseases

association of with HIV, measures and study design for, 312

clinic population for, tuberculosis screening in, 299

control measures for, social network concepts in, 24

crack cocaine use and, in adolescents vs. adults, 511

in developing countries, treatment of, 262 (editorial)

etiology of, in females in Burkina Faso, Africa, 151

incidence and prevalence of, in HIV, 230

incident, risk factors for, in young men, 198

laboratory diagnosis of, CDC survey of, 342

self-medication for

HIV infection and, in Thai men, 264

for prevention, 353 (editorial)

sexual intercourse during menstruation and, 395

Sexually Transmitted Diseases, future directions for, 261 (editorial)

Sexual mixing patterns, among STD clinic attendees, 248

Social network concepts, in STD control, 24

Socioeconomic status, syphilis and, 1 (editorial), 9

Specimens

tampon-collected, for *C. trachomatis* PCR, 461, 127

urine, for *C. trachomatis*, for ligase chain reaction, 402

vs. polymerase chain reaction, 97

Spermicides, condom use and, in sex workers, 206

Syphilis. *See also* *Treponema pallidum*

care providers for, in southeastern U.S., 40

case-finding in, screening vs. contact tracing for, 51, 441 (letter)

control measures for

availability of, 40

biomedical issues in, 5

historic and epidemiologic basis for, 68

early, detection of *T. pallidum* in, ELISA for, 366

epidemic, transmission of, mathematical models for, 30

epidemiology of, from 1941-1993, 16

in female commercial sex workers, incidence, prevalence, and de-

terminants of, 120

neurologic. *See* Neurosyphilis

penile cancer risk and, 453

persistence of, in southeastern U.S., 1 (editorial), 9

prevention of, 1 (editorial), 9

three-tiered strategy for, 58

serologic screening for, 45

Syva MicroTrak enzyme immunoassay, for *C. trachomatis*, confirmation of with Syva Direct specimen test, 494

T

Tampon-collected specimens, for *C. trachomatis*, 461, 127

Telephone, HIV post-test counseling by, 190

Telephone hotline, CDC, caller profiles for, 131

Tetracycline, *N. gonorrhoeae* resistance to, 379

Thai men, STD self-treatment by, HIV infection and, 264

Third World countries. *See* Developing countries

Thompson, Sumner E., 471, obituary, 168

Treponema pallidum. *See also* Syphilis

detection of in early syphilis, ELISA for, 366

Trichomonas vaginalis, risk factors for, in China, 415

Trichomoniasis, incidence and prevalence of, in females in Burkina Faso, Africa, 151

Tuberculosis, screening for, in STD clinic, 299

U

Unsafe sex practices. *See* High-risk behavior

Urban poor, female, condom use and HIV test-seeking in, predictors of, 357

Urethritis, nongonococcal, history of, 86 (Parran lecture)

V

Vaccine, *C. trachomatis*, 145

Vaginal tampons, *C. trachomatis* sample collection from, 461, 127

Vaginitis, bacterial

incidence and prevalence of, in females in Burkina Faso, Africa, 151

polymorphonuclear neutrophils absence in, 489

VIDAS enzyme-linked fluorescent assay, for *C. trachomatis*, 115

Visuwell test, for *T. pallidum* detection in early syphilis, 366

W

Warts, anogenital, scissors excision of, 273

Z

Zambia, partner notification in, 289